Main

processing priority

4

site type

3 (personal blog or private political site, e.g. Blogspot, Substack, also small blogs on own domains)

review version

11

html import

20 (imported)

Events

first seen date

2024-03-08 05:59:22

expired found date

-

created at

2024-06-06 15:18:42

updated at

2026-03-01 19:30:44

Domain name statistics

length

15

crc

36097

tld

2211

nm parts

0

nm random digits

0

nm rare letters

0

Connections

is subdomain of id

-

previous id

0

replaced with id

0

related id

-

dns primary id

54242416

dns alternative id

0

lifecycle status

0 (unclassified, or currently active)

Subdomains and pages

deleted subdomains

0

page imported products

0

page imported random

0

page imported parking

0

Error counters

count skipped due to recent timeouts on the same server IP

0

count content received but rejected due to 11-799

0

count dns errors

0

count cert errors

0

count timeouts

0

count http 429

0

count http 404

0

count http 403

0

count http 5xx

0

next operation date

-

Server

server bits

server ip

-

Mainpage statistics

mp import status

20

mp rejected date

-

mp saved date

-

mp size orig

298656

mp size raw text

54531

mp inner links count

177

mp inner links status

20 (imported)

Open Graph

title

Med-Chemist

description

image

site name

author

updated

2025-12-17 08:05:19

raw text

Med-Chemist Med-Chemist : "Quintessential Medicinal Chemistry" Friday, March 8, 2024 FDA Approves Skyclarys (omaveloxolone) for the Treatment of Friedreich’s Ataxia In continuation of my update on omaveloxolone Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced   the U.S. Food and Drug Administration (“FDA”) approval of  Skyclarys™ (omaveloxolone) for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older. With this approval, the FDA granted a rare pediatric disease priority review voucher. "The approval of Skyclarys, the first therapy specifically indicated for the treatment of Friedreich’s ataxia, is an important milestone for patients affected by this disease as well as their families and caregivers," said Warren Huff, Reata's Chief Executive Officer. "We are grateful to Friedreich’s ataxia patients, investigators, U.S. regulators, and our scientists and employees who made this approval possible. As a company, this is a transformative...

Text analysis

redirect type

0 (-)

block type

0 (no issues)

detected language

1 (English)

category id

Nowotwory (78)

index version

2025110801

spam phrases

0

Text statistics

text nonlatin

0

text cyrillic

0

text characters

44175

text words

8066

text unique words

1753

text lines

507

text sentences

268

text paragraphs

100

text words per sentence

30

text matched phrases

19

text matched dictionaries

13

RSS

rss status

32 (unknown)

rss found date

2025-03-21 10:46:11

rss size orig

490728

rss items

25

rss spam phrases

10

rss detected language

1 (English)

inbefore feed id

-

inbefore status

0 (new)

Sitemap

sitemap status

34 (reserved: import paused pending content quality/relevance assessment after importing first 500 pages)

sitemap review version

2

sitemap urls count

2929

sitemap urls adult

0

sitemap filtered products

0

sitemap filtered videos

0

sitemap found date

2024-03-11 05:32:52

sitemap process date

2025-05-09 20:21:50

sitemap first import date

-

sitemap last import date

2026-03-01 19:30:44